Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

Patients with diabetes taking a semaglutide medication face a higher risk of NAION, a potentially debilitating ophthalmic condition. Semaglutide medication use is linked with a greater risk of ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Losing weight is a common New Year’s resolution, and many people are now turning to advanced weight-loss medications like ...

Here’s some of our top analysis to help you make sense of it all. Accountable care organizations and healthcare providers are ...